Page last updated: 2024-12-06

inogatran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Inogatran is a potent and selective thrombin inhibitor that was developed as a potential anticoagulant agent. It is a small-molecule compound that directly binds to the active site of thrombin, preventing its ability to cleave fibrinogen and initiate blood clot formation. Inogatran has shown promising preclinical activity in animal models, demonstrating its effectiveness in preventing thrombosis and reducing stroke risk. However, inogatran has not been approved for clinical use due to concerns regarding its pharmacokinetic properties and potential for side effects. Nevertheless, it serves as a valuable tool for studying thrombin inhibition and exploring new anticoagulant therapies.'

inogatran: a direct low molecular weight thrombin inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66005
CHEMBL ID114715
SCHEMBL ID22747
SCHEMBL ID22745
MeSH IDM0262057

Synonyms (25)

Synonym
bdbm50073316
{(r)-1-cyclohexylmethyl-2-[(s)-2-(3-guanidino-propylcarbamoyl)-piperidin-1-yl]-2-oxo-ethylamino}-acetic acid
n-((1r)-2-cyclohexyl-1-(((2s)-2-((3-guanidinopropyl)carbamoyl)piperidino)carbonyl)ethyl)glycine
inogatran [inn]
inogatran
{[(1r)-2-((2s)-2-{[(3-{[amino(imino)methyl]amino}propyl)amino]carbonyl}piperidinyl)-1-(cyclohexylmethyl)-2-oxoethyl]amino}acetic acid
inogatran (astra-zeneca)
1K21
2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid
CHEMBL114715 ,
h-314-27
428409i84l ,
h 314-27
h314-27
unii-428409i84l
155415-08-0
n-(2-(2-(((3-((aminoiminomethyl)amino)propyl)amino)carbonyl)-1-piperidinyl)-1-(cyclohexylmethyl)-2-oxo-ethyl)glycine
SCHEMBL22747
SCHEMBL22745
DTXSID50165895
CS-6745
HY-19660
n-[(1r)-2-{(2s)-2-[(3-carbamimidamidopropyl)carbamoyl]piperidin-1-yl}-1-(cyclohexylmethyl)-2-oxoethyl]glycine
Q6036513
AKOS040733453

Research Excerpts

Effects

ExcerptReferenceRelevance
"Inogatran has no effect on platelet aggregation induced by ADP or collagen."( In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor.
Bylund, R; Eriksson, U; Gustafsson, D; Gyzander, E; Teger-Nilsson, AC, 1997
)
1.34

Treatment

Inogatran-treated pigs showed a dose-dependent antithrombotic effect. The average patency rates were 34 +/- 39, 54 +/- 37 and 80 +/- 32%, in groups 6, 7 and 8.

ExcerptReferenceRelevance
"Inogatran-treated pigs showed a dose-dependent antithrombotic effect, and the average patency rates were 34 +/- 39, 54 +/- 37 and 80 +/- 32%, in groups 6, 7 and 8, respectively."( Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis.
Grip, L; Mattsson, C; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1996
)
1.31
"Treatment with inogatran resulted in median activated partial thromboplastin times after 24 h of 36, 44 and 53 s in the low, medium and high dose inogatran groups, respectively, as compared to 54 s in the heparin group (ns). "( A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
, 1997
)
0.9

Pharmacokinetics

ExcerptReferenceRelevance
" After intravenous administration the half-life was short in all three animal species, due to a small volume of distribution and a relatively high clearance."( Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.
Bredberg, U; Eriksson, UG; Regårdh, CG; Renberg, L; Teger-Nilsson, AC, 1998
)
0.6
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33

Bioavailability

The oral bioavailability of inogatran was incomplete, presumably due to a low membrane permeability, and dose dependent. There was a 5-fold increase in the bioavailability in the presence of aprotinin.

ExcerptReferenceRelevance
" The oral bioavailability of inogatran was incomplete, presumably due to a low membrane permeability, and dose dependent."( Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug.
Bredberg, U; Eriksson, UG; Regårdh, CG; Renberg, L; Teger-Nilsson, AC, 1998
)
0.89
"The objective of the study was to investigate the mechanisms behind increased bioavailability of an enzymatically stable thrombin inhibitor, inogatran, after coadministration with a trypsin inhibitor, aprotinin."( Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement.
Lindfors, L; Sjöström, M; Ungell, AL, 1999
)
0.5
" There was a 5-fold increase in the bioavailability of inogatran in the presence of aprotinin."( Inhibition of binding of an enzymatically stable thrombin inhibitor to lumenal proteases as an additional mechanism of intestinal absorption enhancement.
Lindfors, L; Sjöström, M; Ungell, AL, 1999
)
0.55

Dosage Studied

ExcerptRelevanceReference
" The thrombin inhibitors were given intravenously, and complete concentration- and/or dose-response curves were constructed."( The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Deinum, J; Elg, M; Gustafsson, D, 1997
)
0.3
" The present study indicates that clinically relevant concentrations of the tested thrombin inhibitors interfere with endothelial-mediated APC generation, which may offer an explanation for the lack of a dose-response effect in clinical trials with thrombin inhibitors."( Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Frebelius, S; Jansson, K; Linder, R; Swedenborg, J, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain H, ProthrombinHomo sapiens (human)Ki0.00420.00400.00410.0042AID977610
Chain H, ProthrombinHomo sapiens (human)Ki0.00420.00400.00410.0042AID977610
ProthrombinHomo sapiens (human)IC50 (µMol)7.90570.00000.710710.0000AID210672; AID210676; AID210821
ProthrombinHomo sapiens (human)Ki0.01140.00000.78469.0000AID1525519; AID210990; AID211233
Cationic trypsinBos taurus (cattle)Ki0.67500.00001.07539.0000AID215217
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID211233The inhibitory activity against thrombin (IIa)1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety.
AID215029Inhibition of trypsin 1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety.
AID210676Inhibition against platelet aggregation without interacting directly with the nucleophilic serine of thrombin.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID210821In vitro for the inhibition of thrombin2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography.
AID1918194Lipophilicity, log D of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1918193Dissociation constant, pKa of the compound2022Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21
Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID210990Binding affinity against Thrombin.2000Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
Protease inhibitors: current status and future prospects.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID215217The inhibitory activity against trypsin1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety.
AID1525519Inhibition of thrombin (unknown origin)2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Why Some Targets Benefit from beyond Rule of Five Drugs.
AID210672Inhibition of thrombin (IIa)1998Bioorganic & medicinal chemistry letters, Dec-15, Volume: 8, Issue:24
Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Oct-26, Volume: 313, Issue:3
Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Oct-26, Volume: 313, Issue:3
Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's26 (60.47)18.2507
2000's14 (32.56)29.6817
2010's2 (4.65)24.3611
2020's1 (2.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.11 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (27.27%)5.53%
Reviews3 (6.82%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (65.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]